Trends for Growth in a Post-COVID ERA
As the world navigates the second year of the COVID-19 pandemic, thoughts extend to both current and future trends in biotechnology. What are some of the trends that might affect the industry?
The pandemic underlined a critical need for upgrading healthcare access. Biotech can help address this for populations that have limited healthcare access, both for chronic disease and even in aiding the vaccine rollout for COVID-19. This creates an opportunity for technological solutions to help get both acute and long-term health issues addressed, no matter where people are.
Research for Disease
The pandemic also brought to the forefront the need to address research and innovation, for vaccines, preventative treatments, and treatments for active infections. Investments in research and development for infectious disease, combined with the need for new therapies and potential cures for chronic disease, will continue to drive growth in the market.
Some examples of research areas include cell and gene therapy, rare and orphan disease, Alzheimer’s disease, and more.
Biotechnology has been a potential growth area when related to agricultural markets. Agriculture has remained a burgeoning opportunity for biotech without the influence of COVID-19, and will continue to do so.
Ongoing Pandemic Concerns
Given the early stages of vaccine rollout, the COVID-19 pandemic is not over. Greater access to vaccines around the world is essential to helping bring the crises to an end. Additional research for therapeutics will continue to drive technology. Some examples of this include mRNA vaccine delivery and RNAi therapies for gene manipulation.
Advances in genetics will continue apace, and the demand for accessible telemedicine and care will feature for the foreseeable future.
Because COVID-19 has affected the public more than any other crises, it is likely that a lens will remain turned toward public health across the board, providing numerous opportunities for investment.
The abrupt workflow of regulatory processes during the pandemic has had powerful ramifications in biotech. Clinical trial disruption and other concerns come into play. It remains paramount to try and continue business as usual and stay on top of regulatory demands and documentation.
Qualer: Filling a Niche
Qualer is here to help you navigate this constantly evolving landscape in your business. We can help you maintain your regulatory records to ensure audit readiness. We provide software to help you manage your laboratory assets, saving you from work downtime and saving you money.
While many trends can be forecast, there will always be surprises. Let Qualer help guide your business with our collaborative ecosystem, giving you up-to-the-minute status reports and helping you stay at the forefront of preparedness.
Drug Discover & Development: How COVID-19 has affected Big Pharma and biotech
RBC Capital Markets: Biotech Outlook 2021: Innovation, IPOs and COVID‑19 https://www.rbccm.com/en/gib/biopharma/episode/biotech-outlook-2021-innovation-ipos-and-covid-19